Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
View in:
PubMed
subject areas
Adolescent
Adult
Antineoplastic Agents
Biomarkers, Tumor
Female
fms-Like Tyrosine Kinase 3
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Mutation
Neoplasm Recurrence, Local
Prognosis
Prospective Studies
Staurosporine
Survival Rate
Young Adult
authors with profiles
Richard A. Larson